| 10736878 |
Treatment of organophosphate exposure with triptans |
David B. Fick, Ernest H. Pfadenhauer, James Lucot |
2020-08-11 |
|
| 10646457 |
Emesis treatment |
James Lucot |
2020-05-12 |
|
| 10478438 |
Treatment of organophosphate exposure with ocinaplon |
Ernest H. Pfadenhauer |
2019-11-19 |
|
| 10398687 |
Use of cyproheptadine to treat organophosphate exposure |
David B. Fick |
2019-09-03 |
|
| 10206889 |
Emesis treatment |
James Lucot |
2019-02-19 |
|
| 9918949 |
Emesis treatment |
James Lucot |
2018-03-20 |
|
| 8734818 |
Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives |
Alvin J. Glasky, David B. Fick |
2014-05-27 |
$4,659,000 |
| 8637263 |
Assay for determination of compounds having anti-emetic activity |
David B. Fick, Ernest H. Pfadenhauer |
2014-01-28 |
|
| 8598180 |
Tetrahydroindolone derivatives for treatment of neurological conditions |
David B. Fick, Jason Sharp, Ernest H. Pfadenhauer |
2013-12-03 |
|
| 8377456 |
Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives |
Alvin J. Glasky, David B. Fick |
2013-02-19 |
$7,339,000 |
| 8063233 |
Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives |
Alvin J. Glasky, David B. Fick |
2011-11-22 |
$8,776,000 |
| 7795266 |
Tetrahydroindolone derivatives for treament of neurological conditions |
David B. Fick, Jason Sharp, Ernest H. Pfadenhauer |
2010-09-14 |
|
| 7531670 |
Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives |
Alvin J. Glasky, David B. Fick |
2009-05-12 |
$3,212,000 |
| 6982269 |
Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives |
Alvin J. Glasky, David B. Fick |
2006-01-03 |
$1,176,000 |
| 6936601 |
Compositions for treating pain |
Harlan E. Shannon, Daniel E. Womer, Mary Jeanne Kallman |
2005-08-30 |
$148,835,000 |
| 6770638 |
Tetrahydroindolone and purine derivatives linked to arylpiperazines |
David B. Fick, Mark M. Foreman, Alvin J. Glasky |
2004-08-03 |
$1,554,000 |
| 6444665 |
Method for treating pain |
Harlan E. Shannon, Daniel E. Womer, Mary Jeanne Kallman |
2002-09-03 |
$141,811,000 |
| 6258807 |
Method for treating pain |
Harlan E. Shannon, Daniel E. Womer, Mary Jeanne Kallman |
2001-07-10 |
$472,227,000 |
| 6242462 |
Pharmacological agents |
David Bleakman, Iyengar Smriti, David Lodge, Paul Leslie Ornstein |
2001-06-05 |
$240,697,000 |
| 5925680 |
Synthetic excitatory amino acids |
James Allen Monn, Darryle D. Schoepp, Joseph P. Tizzano |
1999-07-20 |
$331,085,000 |
| 5916920 |
3-substituted Bicyclo3.1.0!hexane-6-carboxylic acids |
Carmen Dominguez Fernandez, Steven Marc Massey, James Allen Monn |
1999-06-29 |
$140,499,000 |
| 5882671 |
Anxiolytic agents |
Mary Jeanne Kallman, James Allen Monn, Darryle D. Schoepp, Joseph P. Tizzano |
1999-03-16 |
$734,222,000 |
| 5717109 |
Excitatory amino acid receptor antagonists |
M. Brian Arnold, Thomas John Bleisch, Mary Jeanne Kallman, Paul Leslie Ornstein, Darryle D. Schoepp +1 more |
1998-02-10 |
$225,440,000 |
| 5661184 |
Psychiatric agents |
Mary Jeanne Kallman, James Allen Monn, Darryle D. Schoepp, Joseph P. Tizzano |
1997-08-26 |
$86,535,000 |
| 5399565 |
Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof |
Beverley Greenwood, J. Jeffry Howbert, Steven J. Mitan, Kurt Rasmussen |
1995-03-21 |
$33,211,000 |
